CRSP
CRISPR Therapeutics AG
There isn't enough reported data to score CRSP yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
CRSP Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
CRSP's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CRSP PE Valuation
CRSP has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CRSP Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect CRSP's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CRSP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$4.69 | +$0.87 |
| Q2 2026 | -$4.71 | +$0.69 |
| Q1 2026 | -$6.17 | -$1.68 |
| Q4 2025 | -$6.47 | -$2.13 |
| Q3 2025 | -$5.56 | -$2.75 |
| Q2 2025 | -$5.40 | -$2.19 |
| Q1 2025 | -$4.49 | -$1.79 |
| Q4 2024 | -$4.34 | -$2.40 |
CRSP is still losing money, but less than at its worst: $4.69 per share over the past year, against $8.52 at its worst in late 2022.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CRSP on earnings quality, reporting a profit while its opponent remains loss making.
CRSP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $12.7M | +1325% |
| Q2 2026 | $10.2M | +1041% |
| Q1 2026 | $1.5M | +69% |
| Q4 2025 | $864K | -98% |
| Q3 2025 | $889K | +48% |
| Q2 2025 | $892K | +73% |
| Q1 2025 | $865K | +72% |
| Q4 2024 | $35.7M | -82% |
CRSP's revenue is recovering but still below its 2021 peak: $13M last quarter, up 1325% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1026% | +13828 points |
| Q2 2026 | -1152% | +24557 points |
| Q1 2026 | -8933% | +8226 points |
| Q4 2025 | -17913% | -17732 points |
| Q3 2025 | -14855% | +3439 points |
| Q2 2025 | -25709% | +3548 points |
| Q1 2025 | -17159% | +10735 points |
| Q4 2024 | -181% | -216 points |
CRSP's operating margin was −1026% last quarter, up 13828 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over CRSP on profitability, with a higher operating margin.
CRSP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$90.1M | -$5.4M |
| Q2 2026 | -$84.1M | +$29.9M |
| Q1 2026 | -$109.4M | -$55.2M |
| Q4 2025 | -$93.1M | -$42.8M |
| Q3 2025 | -$84.7M | +$22.4M |
| Q2 2025 | -$114M | -$17.7M |
| Q1 2025 | -$54.2M | -150% |
| Q4 2024 | -$50.3M | +$46.5M |
CRSP has burned cash in almost every quarter: −$377M over the past year, against −$303M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over CRSP on cash generation, producing positive trailing cash flow while its opponent burns cash.
CRSP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +227K shares |
| 1 year | +6% | +5.4M shares |
| 3 years | +22% | +17.3M shares |
| 5 years | +27% | +20.5M shares |
| Available history | +61% | +36.5M shares |
CRSP has 97M diluted shares, up 6% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over CRSP on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
CRSP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2022 | -2.1x | Net Cash |
| Q4 2021 | -2.4x | Net Cash |
| Q3 2021 | -2.4x | Net Cash |
| Q2 2021 | -3.6x | Net Cash |
| Q2 2020 | -329.4x | Net Cash |
| Q1 2020 | -32.3x | Net Cash |
| Q4 2019 | -18.3x | Net Cash |
CRSP has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CRSP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.7 | Neutral |
| Stochastic | 17.4 | Oversold |
CRSP's weekly RSI is 39 (neutral) and its Stochastic is 17 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CRSP PE vs Healthcare Sector
| Metric | CRSP | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CRSP has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CRSP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $50.7 | 16% below |
| 20 week MA | $52.5 | 19% below |
| 50 week MA | $52.7 | 19% below |
| 100 week MA | $50.8 | 16% below |
| 200 week MA | $53.0 | 20% below |
CRSP is in a downtrend: it's below all five of its weekly moving averages, and 20% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CRSP on trend strength, trading above more of its moving averages.
CRSP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $66.0 | $168.5 | +155% |
| 2021 | $168.5 | $82.2 | -51% |
| 2022 | $82.2 | $44.1 | -46% |
| 2023 | $44.1 | $62.6 | +42% |
| 2024 | $62.6 | $40.0 | -36% |
| 2025 | $40.0 | $55.1 | +38% |
| 2026 YTD | $55.1 | $42.6 | -23% |
CRSP's yearly returns have swung widely, from +155% in 2020 to −51% in 2021. It's down 23% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CRSP on returns for 2026, with the stronger performance.